AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20514964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 1 microg/kg (group C1, n=39)
Number of subjects: 120
Study 20514964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 microg/kg (group C2, n=41)
Number of subjects: 120
Study 20514964 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group NS, n=40)
Number of subjects: 120
Study 18628259 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention (PRCI)
Number of subjects: 55
Study 18628259 — intervention group
Group type: COMPARATOR
Intervention: Positive Self‐Affirmative Intervention (PMI)
Number of subjects: 55
Study 16623401 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal low-flow anesthesia (LFA) at 0.3 mL/min
Number of subjects: 40
Study 16623401 — intervention group
Group type: COMPARATOR
Intervention: Semi-closed high flow anesthesia (HFA) at 2 L/min
Number of subjects: 40
Study 16623401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LFA and HFA
Number of subjects: 40
Study 14763696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg bolus IV, followed by 1 mg/kg/hour continuous infusion for 10 hours)
Number of subjects: 40
Study 14763696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL saline IV)
Number of subjects: 40
Study 14763696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 40
Study 14763696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10762509 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive body rotation (+/-30 degrees, 0.01 Hz) in darkness with head held stationary
Number of subjects: 7
Study 10762509 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (10 subjects)
Number of subjects: 7
Study 10762509 — intervention group
Group type: COMPARATOR
Intervention: Left brain-damaged patients (2 patients)
Number of subjects: 7
Study 7871655 — intervention group
Group type: EXPERIMENTAL
Intervention: Pikamilon administration
Number of subjects: 0
Study 7871655 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2893187 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (250 mg 6‐hourly, 500 mg 6‐hourly, or 500 mg 12‐hourly)
Number of subjects: 18
Study 2893187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (with or without zidovudine)
Number of subjects: 18
Study 2893187 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 18
Study 30286443 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (2 mg)
Number of subjects: 95
Study 30286443 — intervention group
Group type: COMPARATOR
Intervention: Dronabinol (10 mg and 30 mg)
Number of subjects: 95
Study 30286443 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (750 mg)
Number of subjects: 95
Study 30286443 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (1500 mg)
Number of subjects: 95
Study 30286443 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (4500 mg)
Number of subjects: 95
Study 30286443 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam and Dronabinol
Number of subjects: 95
Study 30286443 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD (1500 mg and 4500 mg)
Number of subjects: 95
Study 28052063 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW cord blood adiponectin
Number of subjects: 181
Study 28052063 — intervention group
Group type: COMPARATOR
Intervention: Child plasma HMW adiponectin
Number of subjects: 181
Study 28130206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 207
Study 28130206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 207
Study 28130206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 2 mg twice daily
Number of subjects: 207
Study 28130206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 23570278 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored educational intervention for oncologists involving standardized patient instructors (SPIs)
Number of subjects: 400
Study 23570278 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching intervention for patients and caregivers to facilitate prioritizing and discussing questions and concerns
Number of subjects: 400
Study 21541241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy with gemcitabine (1250 mg/m² on days 1 and 4), cisplatin (75 mg/m² on day 2), and erlotinib (150 mg daily on days 5-15, followed by maintenance erlotinib)
Number of subjects: 24
Study 21541241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent chemotherapy with gemcitabine, cisplatin, and erlotinib
Number of subjects: 24
Study 19541016 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (0.067 g kg(‐1) h(‐1))
Number of subjects: 16
Study 19541016 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 16
Study 17944739 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (botox) 4 x 25 U
Number of subjects: 23
Study 17944739 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 23
Study 17944739 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (botox and saline)
Number of subjects: 23
Study 15178915 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day)
Number of subjects: 52
Study 15178915 — intervention group
Group type: COMPARATOR
Intervention: Loratadine (10 mg/day)
Number of subjects: 52
Study 11157322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat diet (LF)
Number of subjects: 11
Study 11157322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat and energy diet (LFE)
Number of subjects: 11
Study 11157322 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy diet (LE)
Number of subjects: 11
Study 11157322 — intervention group
Group type: COMPARATOR
Intervention: Typical fat diet (TF)
Number of subjects: 11
Study 10101928 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic subjects
Number of subjects: 86
Study 10101928 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic subjects with nephropathy and coronary vascular disease (CVD)
Number of subjects: 86
Study 10101928 — intervention group
Group type: COMPARATOR
Intervention: Type II diabetics
Number of subjects: 86
Study 10101928 — intervention group
Group type: COMPARATOR
Intervention: Overweight controls
Number of subjects: 86
Study 10101928 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetic patients with diabetic neuropathy, nephropathy or CHD
Number of subjects: 86
Study 7833483 — intervention group
Group type: COMPARATOR
Intervention: Standard random single-donor platelet transfusions (mean leukocytes, 430 x 10(6) per transfusion)
Number of subjects: 75
Study 7833483 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted random single-donor platelet transfusions (mean leukocytes, 2 x 10(6) per transfusion)
Number of subjects: 75
Study 7833483 — intervention group
Group type: COMPARATOR
Intervention: Standard random single-donor platelet transfusions
Number of subjects: 75
Study 7833483 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted random single-donor platelet transfusions
Number of subjects: 75
Study 2086423 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction-cup oculopression (SCO; negative pressure -100 and -150 mmHg)
Number of subjects: 40
Study 2086423 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia (RBA) with 5 ml of bupivacaine/lidocaine mixture with adrenaline
Number of subjects: 40
Study 2086423 — intervention group
Group type: EXPERIMENTAL
Intervention: Vörösmarthy oculopression (VMO; pressure 30 and 40 mmHg)
Number of subjects: 40
Study 678373 — intervention group
Group type: EXPERIMENTAL
Intervention: Propanidid and lignocaine
Number of subjects: 0
Study 678373 — intervention group
Group type: COMPARATOR
Intervention: Existing practice of non-depolarizing neuromuscular blocking drugs
Number of subjects: 0
Study 31007057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 47
Study 29761313 — intervention group
Group type: EXPERIMENTAL
Intervention: Yisui Shengxue Granules (12 g/bag three times a day) for 3 months
Number of subjects: 40
Study 29761313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29761313 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis from 5 patients in the experimental group
Number of subjects: 40
Study 27456034 — intervention group
Group type: EXPERIMENTAL
Intervention: sarpogrelate in addition to aspirin
Number of subjects: 186
Study 27456034 — intervention group
Group type: COMPARATOR
Intervention: non-sarpogrelate group
Number of subjects: 186
Study 27456034 — intervention group
Group type: EXPERIMENTAL
Intervention: sarpogrelate
Number of subjects: 186
Study 27456034 — intervention group
Group type: COMPARATOR
Intervention: non-sarpogrelate
Number of subjects: 186
Study 25212518 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 343
Study 25212518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 25212518 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 343
Study 23905874 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor now
Number of subjects: 22
Study 23905874 — intervention group
Group type: COMPARATOR
Intervention: Mentor later (waitlist control)
Number of subjects: 22
Study 21610441 — intervention group
Group type: EXPERIMENTAL
Intervention: Lift-and-slide technique
Number of subjects: 6
Study 21610441 — intervention group
Group type: COMPARATOR
Intervention: Log roll technique
Number of subjects: 6
Study 19700005 — intervention group
Group type: EXPERIMENTAL
Intervention: Online CBT in addition to usual care (n=149)
Number of subjects: 297
Study 19700005 — intervention group
Group type: COMPARATOR
Intervention: Usual care from general practitioner while on an 8‐month waiting list for online CBT (n=148)
Number of subjects: 297
Study 16701923 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (n=16)
Number of subjects: 30
Study 16701923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=15)
Number of subjects: 30
Study 15270891 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical photodynamic therapy with methyl aminolaevulinate
Number of subjects: 17
Study 15270891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11274904 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-fuzzy control system (group A)
Number of subjects: 40
Study 11274904 — intervention group
Group type: COMPARATOR
Intervention: Conventional algorithm (control group B)
Number of subjects: 40
Study 8996461 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional TENS applied to the ipsilateral forearm
Number of subjects: 16
Study 8996461 — intervention group
Group type: COMPARATOR
Intervention: Conventional TENS applied to the contralateral leg
Number of subjects: 16
Study 7981402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric approach for predictive distribution
Number of subjects: 0
Study 3582898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metenkephalin analogue (40 micrograms i.v.)
Number of subjects: 17
Study 3582898 — intervention group
Group type: EXPERIMENTAL
Intervention: Metenkephalin analogue (20 to 60 micrograms i.v.)
Number of subjects: 17
Study 31365437 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy adapted for cognitive impairments (CBT‐ABI), 9 sessions
Number of subjects: 45
Study 30032941 — intervention group
Group type: EXPERIMENTAL
Intervention: MICO therapist behaviors (simple reflections and paraphrasing reflections)
Number of subjects: 132
Study 30032941 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex reflections and open questions
Number of subjects: 132
Study 30032941 — intervention group
Group type: COMPARATOR
Intervention: Closed questions
Number of subjects: 132
Study 30032941 — intervention group
Group type: EXPERIMENTAL
Intervention: Open questions and complex reflections
Number of subjects: 132
Study 27578124 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin E supplementation (1200 IU/d for 12 weeks)
Number of subjects: 60
Study 26598197 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival air polishing
Number of subjects: 31
Study 26598197 — intervention group
Group type: COMPARATOR
Intervention: Manual scaling
Number of subjects: 31
Study 21944571 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support worker (PSW) service
Number of subjects: 2724
Study 21944571 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2724
Study 20690154 — intervention group
Group type: EXPERIMENTAL
Intervention: Long hydrophilic-coated sheath
Number of subjects: 351
Study 20690154 — intervention group
Group type: COMPARATOR
Intervention: Short sheath (control group)
Number of subjects: 351
Study 18403134 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (25-100mg daily)
Number of subjects: 147
Study 18403134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 15892078 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Number of subjects: 0
Study 15892078 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 12925458 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 264
Study 12925458 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 264
Study 10802078 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate patches, 0.1 mg/h
Number of subjects: 88
Study 10802078 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 88
Study 8803306 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate depot (LA) 3.75 mg injected subcutaneously every 28 days
Number of subjects: 45
Study 8803306 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 800 mg daily oral dose
Number of subjects: 45
Study 1320563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (two puffs qid 2 mg/puff)
Number of subjects: 12
Study 1320563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1320563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 12
Study 6829434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg)
Number of subjects: 44
Study 6829434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 31053215 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal (IR) + Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 108
Study 31053215 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 108
Study 29562846 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 120
Study 29562846 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 120
Study 29562846 — intervention group
Group type: COMPARATOR
Intervention: Routine procedures
Number of subjects: 120
Study 26974539 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of febuxostat 40-mg tablet
Number of subjects: 24
Study 26974539 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of febuxostat 40-mg tablet
Number of subjects: 24
Study 26974539 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of febuxostat 80-mg tablet
Number of subjects: 24
Study 26974539 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of febuxostat 80-mg tablet
Number of subjects: 24
Study 25112082 — intervention group
Group type: EXPERIMENTAL
Intervention: Xunjingcuiqi needling technique
Number of subjects: 100
Study 25112082 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 100
Study 21546512 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-quadrant technique (5 ml inferonasal and 5 ml superotemporal injection of 50:50 mixture of 2% lidocaine and 0.5% bupivacaine with 150 IU hyaluronidase)
Number of subjects: 54
Study 21546512 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-quadrant technique
Number of subjects: 54
Study 21546512 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard 5 ml single inferonasal injection of 50:50 mixture of 2% lidocaine and 0.5% bupivacaine with 150 IU hyaluronidase)
Number of subjects: 54
Study 21546512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 19876576 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the pelvic floor
Number of subjects: 45
Study 19876576 — intervention group
Group type: COMPARATOR
Intervention: Vaginal cone therapy
Number of subjects: 45
Study 17245662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help workbook based on behavioral principles, modified from the CRAFT model
Number of subjects: 186
Study 17245662 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help workbook plus telephone support
Number of subjects: 186
Study 17245662 — intervention group
Group type: COMPARATOR
Intervention: Treatment resource information package (Control)
Number of subjects: 186
Study 17245662 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (Self-help workbook and Self-help workbook plus telephone support)
Number of subjects: 186
Study 17245662 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including Control)
Number of subjects: 186
Study 15119980 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 7.5 mg
Number of subjects: 131
Study 15119980 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 15 mg
Number of subjects: 131
Study 11437205 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position with bi-optic scanner
Number of subjects: 10
Study 11437205 — intervention group
Group type: COMPARATOR
Intervention: Standing position with single window scanner
Number of subjects: 10
Study 11437205 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position with bi-optic scanner
Number of subjects: 10
Study 11437205 — intervention group
Group type: COMPARATOR
Intervention: Sitting position with single window scanner
Number of subjects: 10
Study 9543434 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy or combination therapy with ritonavir
Number of subjects: 131
Study 9543434 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with ritonavir or combination therapy with ritonavir and zidovudine
Number of subjects: 131
Study 8068834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pairwise comparisons in multi-armed clinical trials
Number of subjects: 0
Study 8068834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dunnett's or Tukey's procedure for multiple comparisons
Number of subjects: 0
Study 8068834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonferroni inequality approximation
Number of subjects: 0
Study 8068834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequentially rejective procedure
Number of subjects: 0
Study 2448358 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine (120 mg, twice daily for 3 days)
Number of subjects: 11
Study 2448358 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 29606104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol and/or D-ribose administered for 12 weeks
Number of subjects: 6
Study 29606104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 27252841 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg 3 times a day
Number of subjects: 0
Study 27252841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25527071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel provision through family planning services
Number of subjects: 700
Study 25527071 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir gel provision through CAPRISA research clinics
Number of subjects: 700
Study 22931627 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 328
Study 22931627 — intervention group
Group type: COMPARATOR
Intervention: Control (no epidural analgesia)
Number of subjects: 328
Study 20837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening from age 40, offered annually from age 40 or 41 to age 48.
Number of subjects: 53884
Study 20837718 — intervention group
Group type: EXPERIMENTAL
Intervention: First routine screen
Number of subjects: 53884
Study 20837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent routine screens
Number of subjects: 53884
Study 20837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative false-positive rate over seven screens
Number of subjects: 53884
Study 20837718 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous false-positive recall
Number of subjects: 53884
Study 17582225 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 g DHA and 0.6 g EPA (omega3 group) daily for 6 months
Number of subjects: 204
Study 17582225 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 204
Study 17029137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonviable Lactobacillus acidophilus (LA)
Number of subjects: 174
Study 17029137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 14582816 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Number of subjects: 337
Study 14582816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 337
Study 11314418 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallium alloy (Galloy)
Number of subjects: 50
Study 11314418 — intervention group
Group type: COMPARATOR
Intervention: High copper amalgam (DPI alloy)
Number of subjects: 50
Study 8994319 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 year old hepatitis A vaccine
Number of subjects: 215
Study 8994319 — intervention group
Group type: COMPARATOR
Intervention: newly produced hepatitis A vaccine
Number of subjects: 215
Study 1460210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide at concentrations of 0.03% and 0.06%
Number of subjects: 0
Study 6230296 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (1 mg/kg/day for seven days; 1 mg/kg/weekly thereafter)
Number of subjects: 30